Recro Pharma Inc. (NASDAQ:REPH) has been given a $24.00 price objective by research analysts at Roth Capital in a research report issued on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price target points to a potential upside of 175.55% from the company’s previous close.

Several other research analysts have also commented on the company. Brean Capital initiated coverage on Recro Pharma in a research report on Monday, October 3rd. They set a “buy” rating and a $21.00 price target on the stock. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research report on Wednesday, October 19th. Janney Montgomery Scott initiated coverage on Recro Pharma in a research report on Monday, August 29th. They set a “buy” rating and a $21.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Recro Pharma in a research report on Monday, November 14th. Finally, Aegis initiated coverage on Recro Pharma in a research report on Monday, November 14th. They set a “buy” rating and a $21.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $19.13.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) opened at 8.71 on Monday. The firm’s market capitalization is $105.94 million. Recro Pharma has a 52 week low of $5.59 and a 52 week high of $12.50. The stock’s 50 day moving average price is $7.71 and its 200 day moving average price is $8.33.

TRADEMARK VIOLATION NOTICE: “Recro Pharma Inc. (REPH) Given a $24.00 Price Target by Roth Capital Analysts” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US & international trademark and copyright law. The correct version of this story can be accessed at http://www.dailypolitical.com/2016/11/29/recro-pharma-inc-reph-given-a-24-00-price-target-by-roth-capital-analysts.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Recro Pharma by 0.4% in the second quarter. Vanguard Group Inc. now owns 107,252 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 400 shares during the period. Stonepine Capital Management LLC increased its position in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock valued at $3,408,000 after buying an additional 191,796 shares during the period. BlackRock Fund Advisors increased its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of Recro Pharma during the third quarter valued at $140,000. Institutional investors own 52.28% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.